Clinical evidence dossier
Intensive lifestyle intervention for type 2 diabetes remission
HbA1c
Evidence signal
Evidence signal
Strong
This is an authoritative evidence signal supplied by Clinical Reference. It is not a formal clinical grade, treatment recommendation, or pooled effect estimate.
Evidence snapshot
- Authoritative support records
- 3
- Supporting studies available for review
- 3
- Randomized trials
- 2
- Reported effects
- 3
Clinical conclusion
Intensive lifestyle intervention for type 2 diabetes remission shows a moderate positive evidence signal for improving HbA1c across the studied comparisons.
The conclusion and evidence-signal classification are distinct authoritative fields and are reproduced as published.
Observed effects
Observed study estimates; not a pooled treatment effect.
Change from baseline
Absolute change
−14 mmol/mol to −13 mmol/mol
Change from baseline
Absolute change
−5 percentage to −5 percentage
Evidence composition
- Non-randomized studies
- 0
- Other designs
- 0
- Unresolved designs
- 1
- Magnitude-eligible effects
- 3
Consistency
Consistency classification
Mostly consistent
- Positive
- 2
- No effect
- 1
- Mixed
- 0
- Negative
- 0
Population and applicability
Structured population data were available for 3 of 3 supporting studies. 3 studies described participants with type 2 diabetes. 2 studies described adult participants.
This population information refers to the materialized supporting studies available for review. Omitted support records remain part of the authoritative support accounting and are available through the audit experience.
View reported population descriptions
These descriptions are reported across the supporting studies; they are not a single synthesized population.
- Adults with recently diagnosed Type 2 diabetes.
- Individuals interested in improving physical activity levels.
- Adults with type 2 diabetes seeking dietary interventions.
- Individuals interested in lifestyle changes to improve glycaemic control.
- Patients currently on glucose-lowering medications.
- Midlife women aged 45-65
- Women diagnosed with type 2 diabetes
Limitations
- Evidence uses heterogeneous comparison contexts: baseline_within_group, usual_care.
- 1 supporting study has high, serious, critical, unclear, or unavailable risk-of-bias information.
Supporting evidence
Inspect the authoritative studies and omitted support records for this dossier.